News

Orphazyme initiates directed issue and private placement of shares

Feb 6, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that the Board of Directors has resolved to initiate a directed issue and private placement of up to an aggregate of 7,032,937 new shares and existing shares, at market price as determined by the Board of Directors of the Company through a book-building process, corresponding to approximately 35.16% of the Company’s currently registered share capital.

Orphazyme initiates directed issue and private place

Read more

Preliminary results for 2019 and financial outlook for 2020

Feb 4, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today releases preliminary results for 2019 as well as the financial outlook for 2020.

Preliminary results for 2019 and financial outlook

Read more

Capital increase of 20,650 shares (equivalent to approximately 0.10% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB

Jan 31, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today decided on a capital increase as a result of a directed issue of bonus shares to Kansas Life Sciences Development Company, Inc. (“KLSDC”) and UCL Business Ltd. (“UCLB”). The capital increase was decided pursuant to the Board of Directors’ authorization laid down in Article 3.6 of the Articles of Association. 

Capital increase of 20650 shares in Orphazyme

Read more

Resolutions passed at the Extraordinary General Meeting in Orphazyme A/S

Jan 25, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today held an Extraordinary General Meeting, at which the shareholders passed the following resolutions.

Resolutions passed at the EGM

Read more

Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities

Jan 7, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.

Reporting of transactions in Orphazymes shares made

Read more

Orphazyme announces US Early Access Program for Niemann-Pick disease Type C

Jan 6, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces the availability of an Early Access Program (EAP) in the United States (US) for its investigational drug arimoclomol for the treatment of Niemann-Pick disease Type C (NPC).

Orphazyme announces early access program

Read more

Notice to convene Extraordinary General Meeting in Orphazyme A/S - CORRECTION

Jan 3, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces.

Notice to convene EGM

Notice to convene EGM correction

Read more

Notice to convene Extraordinary General Meeting in Orphazyme A/S

Jan 3, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces.

Notice to convene EGM

Read more

Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C

Jan 3, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces 12-month interim data from an open-label extension of a phase 2/3 study of arimoclomol, an investigational product candidate in development for Niemann-Pick disease Type C (NPC).

Orphazyme reports positive arimoclomol data

Read more

Major shareholder announcement

Dec 19, 2019

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of December 18, 2019 holds a total 991,557 shares in the Company, corresponding to 4.96% of the share capital and that Danske Bank as of December 18, 2019 controls 7.42% of the voting rights in the Company.

Major shareholder announcement

Read more

1 ... 18 19 20 21 22 ... 24